The explosion of generative AI and, specifically, large language models (LLMs), has created renewed energy, focus and promise around the hype of AI impacting the R&D lifecycle. Generative AI is revolutionizing precision medicine clinical trial planning, execution, and operations. Organizations are increasingly recognizing its potential, rallying behind AI initiatives. The race is on – the race to leverage AI as a force multiplier, knowledge amplifier and value generator, ultimately accelerating time-to-insight. In this post, we explore concrete ways in which generative AI can deliver on these promises.